Skip to main content
Premium Trial:

Request an Annual Quote

Sirna Therapeutics Sees Revenues Dwindle, Losses Widen in Q1

NEW YORK, April 29 (GenomeWeb News) - Sirna Therapeutics reported decreased revenues and widening losses for the first quarter on Tuesday.

 

Revenues for the quarter totaled $318,000, down from $490,000 for the year-ago period.

 

R&D expenses for the first quarter were $5.1 million, up from $3.8 million during the same quarter last year.

 

The company's net loss was $5.9 million, or $.19 per share, up from $4.9 million, or $1.62 per share, for the same period last year.

 

As of March 31, Sirna, based in Boulder, Colo., had $29.6 million in cash, cash equivalents, and securities.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.